Table 3.

Hazard ratios of posterior capsule opacification and Nd:YAG capsulotomy, comparing the iSert XY-1 and iSert 251/255 as the index group with the Acrysof (SN60WF) as the reference group using data over the 5-year follow-up period.

Treatment groups		Acrysof (SN60WF)	iSert XY-1	iSert 251/255
Posterior capsule opacification
Crude model	Hazard ratio (95% CI)	Ref	4.54 (1.20, 17.2)	4.88 (1.52, 15.6)
Adjusted model*	Hazard ratio (95% CI)	Ref	7.26 (1.82, 28.8)	8.22 (2.35, 28.7)
Nd:YAG capsulotomy
Crude model	Hazard ratio (95% CI)	Ref	5.89 (1.28, 27.0)	7.32 (1.58, 33.8)
Adjusted model*	Hazard ratio (95% CI)	Ref	6.50 (1.55, 27.2)	8.26 (1.90, 36.0)

Variables included as covariates in the adjusted model were age, sex, diabetes mellitus, and sarcoidosis. The Acrysof IOL (SN60WF) was defined as the reference group and the iSert (XY1 or 251/255) group as the index group.

CI confidence interval, Ref. reference.